艾德生物(300685.SZ)與施維雅達成伴隨診斷合作
格隆匯6月26日丨艾德生物(300685.SZ)公佈,近日,公司與LES LABORATOIRES SERVIER(以下簡稱"施維雅")簽署伴隨診斷合作協議(以下簡稱"本協議"或"協議"),公司自主研發的二代測序(NGS)平台的伴隨診斷產品,用於檢測異檸檬酸脱氫酶(IDH)1和2基因突變;該伴隨診斷產品將用於施維雅的研究性新藥vorasidenib,這是一款突變型異檸檬酸脱氫酶1和2(IDH1和IDH2)的雙重抑制劑,預計在獲批之後可用於治療攜帶IDH突變的瀰漫性腦膠質瘤(LGG)的中國患者。
據悉,施維雅是一家由基金會管理的國際集團,以服務人類健康為宗旨,期望為患者和世界可持續發展帶來意義深遠的社會影響。憑藉其獨特的管理模式,施維雅以發展的眼光充分踐行長期使命:致力於推進治療領域的進展,服務於患者的需求。
公吿稱,以伴隨診斷賦能原研藥物臨牀,推動更多、更好的治療方式服務患者是公司明確的戰略方向。公司藥企朋友圈持續擴大,合作領域、區域不斷擴展,從TKIs靶向藥物、PARPi藥物,到免疫治療藥物、ADC藥物等,均實現了伴隨診斷產品的前瞻性佈局,把握未來市場的創新源頭。此次與施維雅達成伴隨診斷合作,有利於進一步增強公司在腫瘤精準醫療市場的競爭力,將對公司未來的發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.